ALSO READUSFDA refuses admission to drugs manufactured by Ipca Laboratories USFDA refuses admission to APIs manufactured by Ipca Laboratories USFDA bans import of drugs from three plants of Ipca Labs Ipca Laboratories standalone net profit rises 34.76% in the March 2017 quarter IPCA Lab slumps after USFDA bans drugs from three plants
Shares of Ipca Laboratories tanked over 15 per cent today as almost all drugs manufactured by the company at its facilities at Pithampur, Silvassa and Ratlam have been banned from the US market by the country's health regulator.
The stock, after making a weak opening, plummeted 14.83 per cent to Rs 437 on the BSE.
On the NSE, it dived 15.34 per cent to Rs 436.10.
The US Food and Drug Administration (USFDA) cited violation of current good manufacturing norms for its action.
The USFDA has refused admission to all drugs made at the company's Pithampur and Silvassa facility, Ipca Laboratories said in a BSE filing yesterday.
All drugs except API Chloroquine Phosphate made at Ratlam (Madhya Pradesh) unit have also been denied entry in the US, it further said.
The ban on all drugs made at Pithampur (Madhya Pradesh) and Silvassa (Dadra and Nagar Haveli) will continue "until the company can demonstrate that the drugs manufactured from these manufacturing sites and intended for the US market are in compliance with CGMP," Ipca Laboratories added.
However, it said the US health regulator will reconsider the exception for Chloroquine Phosphate made at the Ratlam facility if shortage and/or medical necessity implications change.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)